A Safety and Efficacy Study of Two Dose Levels of Taliglucerase Alfa in Pediatric Subjects With Gaucher Disease

PHASE4CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

May 31, 2012

Study Completion Date

July 31, 2012

Conditions

Gaucher Disease

Interventions

DRUG

Taliglucerase alfa

Taliglucerase alfa for infusion every two weeks for 12 months

Trial Locations (3)

Morningside Medi-Clinic, Morningside

Shaare Zedek Medical Center, Jerusalem

Instituto Privado de Hematologia E Investigacion Clinica (I.P.H.I.C), Barrio Sajonia Asunción